Mylan prices its generic remdesivir in India at $64 per 100 mg vial


6 July 2020 - Mylan will launch a generic version of Gilead Sciences’ COVID-19 anti-viral remdesivir in India at 4,800 rupees, about 80% below the price tag on the drug for wealthy nations.

California-based Gilead has signed licensing deals with several generic drugmakers in an effort to make remdesivir available in 127 developing countries.

Last month, two Indian drugmakers, Cipla and privately-held Hetero Labs, also launched generic versions of the treatment. Cipla will price its version, Cipremi, at less than 5,000 rupees, while Hetero has priced Covifor at 5,400 rupees.

Read CNBC News article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Pricing , India , COVID-19